Pathological Fractures and Musculoskeletal Malignancy DRG Reimbursement

DRG 543 addresses inpatient stays for pathological fractures and musculoskeletal and connective tissue malignancies with a Complication or Comorbidity, encompassing surgical and medical management tied to underlying bone or soft tissue neoplasms. It matters for inpatient reimbursement because presence of a Complication or Comorbidity alters Diagnosis-Related Group assignment and associated Medicare payment weighting.

DRG 543 Overview

DRG 543 covers inpatient episodes for pathological fractures and musculoskeletal and connective tissue malignancies when a Complication or Comorbidity is present. The clinical scope includes fracture management related to underlying bone lesions, treatment of primary or metastatic musculoskeletal tumors, and associated perioperative and medical care. This Diagnosis-Related Group matters for Medicare payment because case classification and the presence of a Complication or Comorbidity affect relative weight and reimbursement for hospital stays. Accurate documentation and coding of the principal diagnosis and any Complication or Comorbidity influence payment assignment within the Medicare Severity Diagnosis-Related Group system.

DRG 543 Overview

Across payers the observed payment range runs roughly from $370 (BCBS min) up to $40K (Anthem max), with mean/median values clustering between about $10K and $17K depending on payer. The widest spread is seen with Anthem where values span up to $40K. See the table and chart below for payer-specific percentiles and distributions.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 543 for the 2023 calendar year. These figures reflect Medicare FFS payment activity at the national level.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$10K	$47K	$7.9K	14K

Patient Population

This DRG’s population skews toward Medicare-age patients rather than primarily working-age commercial members, reflecting a higher proportion of discharges among beneficiaries eligible for Medicare. Commercial payers (Blue Cross Blue Shield, Cigna, Aetna, Anthem) will cover a minority of cases relative to Medicare in national inpatient data. Overall, the cohort is weighted toward older adults, with a mixed but Medicare-dominant payer mix.

Alaska Benchmarks

Alaska shows a wide rate range across payers, from $16K (Anthem and Blue Cross Blue Shield) up to $41K (Cigna), with a state mean near $25K driven upward by Cigna’s upper end. The concentration at $16K for Anthem and BCBS contrasts with Cigna’s notably higher maximum, representing the most significant deviation from national averages. See the table and chart below for payer-level details.

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska with a max of $41K, while Anthem and BCBS are the lowest, both clustered at $16K.
Alaska’s mean rates skew higher due to Cigna’s upper range ($41K), creating a wider state rate spread compared with typical national medians where payers are more clustered around mid-teens to low $20Ks.

Acute surgical and interventional studies assessing fixation techniques and perioperative management for pathological fractures in patients with primary bone tumors or bone metastases. These trials enroll inpatients presenting with pathologic fractures of long bones or spinal collapse, comparing approaches such as intramedullary fixation, endoprosthetic reconstruction, or vertebral augmentation and evaluating outcomes like time to mobilization, perioperative complication rates, blood transfusion needs, and length of stay. Findings inform surgeons and hospital administrators about which acute interventions reduce inpatient resource use and complications for this high-risk population.
Comparative effectiveness research on multimodal oncologic and supportive care strategies to control tumor-related bone destruction and reduce fracture risk. These studies follow patients with musculoskeletal or connective tissue malignancies who receive combinations of systemic therapies, localized radiation, and bone-targeting agents to determine relative impact on subsequent skeletal events, need for emergent admissions, and need for reoperation. Results are relevant to payers and care teams because they identify management pathways that may lower rates of costly inpatient admissions and recurrent surgical interventions.
Post-discharge cohort and outcomes studies evaluating rehabilitation, readmission risk, and long-term functional recovery after inpatient treatment for pathological fractures or musculoskeletal malignancies. These observational studies track discharge disposition, home health or skilled nursing utilization, 30- and 90-day readmissions, durable functional status, and outpatient resource use across patients with differing comorbidity burdens and social supports. Evidence from these studies helps case managers and payers optimize discharge planning, rehabilitation intensity, and transitional care to reduce readmissions and total episode costs for this DRG.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$10K	$47K	$7.9K	14K

Patient Population

Alaska Benchmarks

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska with a max of $41K, while Anthem and BCBS are the lowest, both clustered at $16K.
Alaska’s mean rates skew higher due to Cigna’s upper range ($41K), creating a wider state rate spread compared with typical national medians where payers are more clustered around mid-teens to low $20Ks.

Acute surgical and interventional studies assessing fixation techniques and perioperative management for pathological fractures in patients with primary bone tumors or bone metastases. These trials enroll inpatients presenting with pathologic fractures of long bones or spinal collapse, comparing approaches such as intramedullary fixation, endoprosthetic reconstruction, or vertebral augmentation and evaluating outcomes like time to mobilization, perioperative complication rates, blood transfusion needs, and length of stay. Findings inform surgeons and hospital administrators about which acute interventions reduce inpatient resource use and complications for this high-risk population.
Comparative effectiveness research on multimodal oncologic and supportive care strategies to control tumor-related bone destruction and reduce fracture risk. These studies follow patients with musculoskeletal or connective tissue malignancies who receive combinations of systemic therapies, localized radiation, and bone-targeting agents to determine relative impact on subsequent skeletal events, need for emergent admissions, and need for reoperation. Results are relevant to payers and care teams because they identify management pathways that may lower rates of costly inpatient admissions and recurrent surgical interventions.
Post-discharge cohort and outcomes studies evaluating rehabilitation, readmission risk, and long-term functional recovery after inpatient treatment for pathological fractures or musculoskeletal malignancies. These observational studies track discharge disposition, home health or skilled nursing utilization, 30- and 90-day readmissions, durable functional status, and outpatient resource use across patients with differing comorbidity burdens and social supports. Evidence from these studies helps case managers and payers optimize discharge planning, rehabilitation intensity, and transitional care to reduce readmissions and total episode costs for this DRG.

OpenPayer

Pathological Fractures and Musculoskeletal and Connective Tissue Malignancy with CC: Inpatient Reimbursement Overview

Sign up for drg 543 policy alerts

DRG 543 Overview

OpenPayer

Pathological Fractures and Musculoskeletal and Connective Tissue Malignancy with CC: Inpatient Reimbursement Overview

Sign up for drg 543 policy alerts

DRG 543 Overview

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References